Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab. Objectives: ...
Sight Sciences' analysis shows TearCare can save health plans $36.87 PMPY over traditional dry eye treatments in the U.S. Results from a Budget Impact Analysis indicate that a 20% increase in market ...
Second-generation anaplastic lymphoma kinase (ALK) inhibitors, including ceritinib, brigatinib, and alectinib, have improved survival in ALK-rearranged non-small-cell lung cancer (NSCLC) but are not ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
A phase II study of perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01): Report of interim analysis. This is an ASCO Meeting Abstract from ...
Humacyte, Inc. announced the publication of a Budget Impact Model for its bioengineered human tissue, Symvess, in the Journal of Medical Economics, indicating its cost-effectiveness for hospitals and ...
Have you ever found yourself staring at rows and rows of budget and actual data, wondering how to make sense of it all? You’re not alone. Budget versus actual analysis is one of those tasks that feels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results